Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141323 | 0.88 | ACHE (0.44) | KCNH2ACHEFUCA1GRIN2B | |
| SCHEMBL4132636 | 0.88 | KCNH2 (0.43) | KCNH2ACHEFUCA1GRIN2B | |
| SCHEMBL7242578 | 0.83 | FUCA1 (0.50) | ACHEFUCA1GRIN2B | |
| SCHEMBL4129264 | 0.81 | CHRM2 (0.46) | CHRM3 | |
| SCHEMBL7248714 | 0.79 | FUCA1 (0.46) | ACHEFUCA1GRIN2B | |
| SCHEMBL3527474 | 0.78 | GRIN2B (0.45) | ACHEFUCA1GRIN2B | |
| SCHEMBL4141367 | 0.77 | ALDH1A1 (0.40) | CHRM3KCNH2 | |
| SCHEMBL4136255 | 0.77 | OPRM1 (0.46) | ACHEFUCA1GRIN2B | |
| SCHEMBL4127931 | 0.77 | ADRA1A (0.42) | CHRM3KCNH2 | |
| SCHEMBL4619318 | 0.76 | CHRM3 (0.44) | CHRM3ACHEFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| EP-1934184-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-06-25 | — | — | EP | claimed |
| WO-2007039884-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | claimed |
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1934184-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039884-A1 | 3 -AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885KCNH2 797/4885ACHE 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.